• Evaluate with us, what we believe is a very innovative and promising technology for production in superior eukaryotic systems.
• If you volunteer to beta test the technology with us, you will enjoy a one-shot production of your MAb at a very competitive price and, even better: have access to the compilation of all our beta test results (protein and participant names will of course remain confidential).
  Provided we have enough candidates, the results comparing expression yields, process duration should be statistically meaningful! (take a look at what the report should look like)

As an experienced group of scientist providing, since 2000, custom services for recombinant protein development and production, GTP Technology tries to provide its beloved customers with cutting-edge technologies, when it makes sense for the projects.

The key advantage of the technology is the reduced timescale, from cDNA to established high expression yields cell lines, which translates into faster and less costly USP & DSP development and operation (clic here for further information on comparative advantages of this technology).

To confirm the benefits of this technology over the most used expression strategies in mammalian cells, we are seeking for scientists interested in discovering this potential with their protein of interest.
We will be happy to discuss in details the conditions of this beta-trial with you. Alternatively, you can learn more about the test itself by following this link.
 

After identical expression and purification processes where applied, both proteins were compared by SDS PAGE analysis and protein specific ELISA. While expression yields, purity, migration profiles were identical, differences were observed in the ELISA results: the protein expressed from the newly banked cell line was ineffective for antibody interaction.

Even if the general glycosylation profiles are typical for glycoproteins produced in SF9 insect cells, slight differences are observed:

• 6 different N-glycan types are present on In-house SF9 produced protein and the ELISA tests are positive : Protein-protein interactions occur

• 3 additional N-glycan types are present in commercial SF9 produced protein and the ELISA tests are negative : Protein-protein interactions are quenched

Fig: MALDI TOF MS Analysis: Comparison of the relative intensities of purified permethylated N-glycans  from glycoproteins produced in SF9 cells from two different origins

This result leads to 2 learning for this project:

• Commercial insect cell lines are heterologous. With banking and time, the dominant cell type may differ from one clone to the other. There is therefore an interest in testing several insect cell clones in parallel
• Changes in Glycosylation profiles may impact protein recognition by antibodies or other protein-protein interactions. Characterizing in detail the glycosylation profile of a candidate of interest increases robustness and result consistency.
  

For further information on glycosylation analysis and Proteodynamics : www.proteodynamics.com

Indicia Biotechnology has been offering for more than ten years a wide panel of services in proteomic, ranging from immunoassay development to sample analysis. The company offer spans the entire assay development process and gives access to its expertise on conventional and cutting edge technologies (ELISA, Lateral flow test, Luminex®, Singulex®). As an upstream activity, to provide the highest quality raw biologics, Indicia develops customized polyclonal and monoclonal antibodies, as well as numerous antibody-related services (labeling, affinity purification, characterization...).

Indicia Biotechnology is an ISO 9001 and ISO 13485 certified company.